The Plasma Serotonin and Aortic Stenosis: a Pilot Study.

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to describe the increase in plasma serotonin or 5-hydroxytryptamine (5-HT) in patient with increased severity of aortic stenosis and increased weight cardiac muscle.

Detailed Description
-----------------
Calcific aortic stenosis is the most frequent valve disease in adults. Without therapeutic strategy, this disease leads to heart failure and death. Surgical aortic valve replacement is now a well tolerated cardiac surgery leading to excellent outcomes. Until recently, calcific aortic stenosis was considered to be histopathologically degenerative or passive in origin. It is now recognized, however, as a complex cellular process with features of atherosclerosis. It has been observed that drugs may slow dawn the progression of aortic stenosis in observational studies. It has been suggested that serotonin, a monoamine neurotransmitter and a peripheral signal mediator, may be involved in the progression of aortic stenosis and also in its consequences on myocardium hypertrophy. In the blood, serotonin in mainly stored in platelets, which release serotonin involved in post-injury vasoconstriction, thrombus formation, fibrosis and atherogenesis. This study hypothesized those patients with aortic stenosis exhibit higher circulating serotonin levels than their counterparts without heart disease. In addition to circulating serotonin, its metabolite 5-HIAA will be systematically measured on all patients. This study would allow to determine the potential of plasma serotonin as a prognosis marker and perhaps suggest the discovery of new targets for treatment of aortic stenosis.

Official Title
-----------------
The Plasma Serotonin and Aortic Stenosis: a Pilot Study.

Conditions
-----------------
Aortic Stenosis

Intervention / Treatment
-----------------
* Procedure: biomarkers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group 1 : non aortic stenosis Goup 2, 3 and 4 : aortic stenosis Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Group 1<br>Control group had biomarkers. | Procedure: biomarkers<br>* transthoracic echocardiography, radial, and aortic arterial blood sampling<br>|
| Experimental: Group 2<br>Biomarkers | Procedure: biomarkers<br>* transthoracic echocardiography, radial, and aortic arterial blood sampling<br>|
| Experimental: Group 3<br>Biomarkers | Procedure: biomarkers<br>* transthoracic echocardiography, radial, and aortic arterial blood sampling<br>|
| Experimental: Group 4<br>Biomarkers | Procedure: biomarkers<br>* transthoracic echocardiography, radial, and aortic arterial blood sampling<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurements of 5-HT | Measurement of 5-HT were performed by high pressure liquid chromatography (HPLC) | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurements of acide 5-hydroxy-indol-acetic (5-HIAA) | Measurements of 5-HT monoamine oxidase (MAO)-A-dependent degradation product, 5-HIAA, were performed by HPLC | Baseline | 
| Arterial platelet activation | Arterial platelet activation was assessed by flow cytometry analysis of platelet surface expression of P-selectin and activated integrin GPIIb/IIIa | Baseline |